Implantable Neurostimulators

Implantable Neurostimulators Market Outlook

The global implantable neurostimulators market is projected to reach approximately USD 9.4 billion by 2035, growing at a compound annual growth rate (CAGR) of about 10.2% during the forecast period from 2025 to 2035. The growth of this market can be attributed to the increasing prevalence of neurological disorders, the rising number of patients suffering from chronic pain, and a growing geriatric population. Additionally, advancements in technology and a surge in the usage of neurostimulators for various applications, including pain management and neurological diseases, are expected to propel market growth. Furthermore, the increasing awareness and acceptance of neurostimulation therapies within the healthcare community are contributing to the market's expansion. The rise in outpatient procedures and the demand for minimally invasive treatments are also likely to provide significant momentum to the market growth.

Growth Factor of the Market

One of the primary growth factors driving the implantable neurostimulators market is the rising incidence of chronic pain conditions and neurological disorders such as Parkinson's Disease and epilepsy. As the global population ages, the prevalence of these conditions is expected to increase, leading to a higher demand for neurostimulation therapies. Additionally, advancements in medical technology, including the development of more sophisticated and efficient neurostimulators, are enhancing the effectiveness of treatments and expanding their applications. Innovations in devices, such as rechargeable batteries and wireless technology, are further attracting healthcare providers and patients, making these treatments more appealing. The growing acceptance of neurostimulation devices for chronic pain management and mental health applications, combined with favorable reimbursement policies, is also fostering market growth. These factors collectively underscore the potential for significant expansion in the implantable neurostimulators market.

Key Highlights of the Market

• The market is projected to expand significantly, reaching USD 9.4 billion by 2035.
• North America is anticipated to dominate the market due to advanced healthcare infrastructure.
• Spinal cord stimulators are the leading product type, accounting for a substantial market share.
• Technological advancements such as wireless capabilities are driving innovation in neurostimulators.
• Chronic pain management remains the largest application segment, influencing product development.

By Product Type

Spinal Cord Stimulators :

Spinal cord stimulators (SCS) play a pivotal role in the implantable neurostimulators market, primarily employed for chronic pain management. These devices deliver electrical impulses to the spinal cord, effectively masking pain signals before they reach the brain. SCS units are widely used for conditions such as failed back surgery syndrome and complex regional pain syndrome. The increasing acceptance of SCS as a viable therapeutic option among healthcare providers and patients has greatly contributed to market growth in this segment. Furthermore, advancements in SCS technology, including the development of more sophisticated, programmable devices with improved patient interface, are enhancing their appeal, thus influencing broader adoption in clinical settings.

Deep Brain Stimulators :

Deep brain stimulators (DBS) are critical in the treatment of neurological disorders, particularly Parkinson's Disease and essential tremors. By delivering targeted electrical impulses to specific brain regions, DBS can significantly alleviate symptoms and improve the quality of life for patients. The rising prevalence of Parkinson's Disease across the globe and the shift towards more surgical interventions for symptom management are key factors driving the growth of the DBS segment. Moreover, advancements in device design and programming capabilities are allowing for more personalized treatment options, further propelling the demand for DBS devices. As ongoing research continues to validate the effectiveness of DBS in various other brain-related conditions, the segment is expected to witness substantial growth in the years to come.

Sacral Nerve Stimulators :

Sacral nerve stimulators (SNS) are increasingly recognized for their effectiveness in treating urinary incontinence and other pelvic floor disorders. These devices work by stimulating the sacral nerves, influencing bladder control and function. The growing awareness and acceptance of sacral nerve stimulation as a treatment option for urinary dysfunction are significantly contributing to the expansion of this segment. Additionally, the increasing incidence of urinary incontinence, particularly in the elderly population, is generating demand for innovative treatment options, thus boosting the SNS market. The continuous development of SNS technology, including the introduction of less invasive surgical techniques, is likely to enhance patient experiences and drive further growth in this segment.

Vagus Nerve Stimulators :

Vagus nerve stimulators (VNS) are primarily used to treat epilepsy and treatment-resistant depression. By delivering electrical impulses to the vagus nerve, these devices can modulate brain activity, offering therapeutic benefits for patients who do not respond to conventional treatments. The growing number of epilepsy cases and the increasing recognition of VNS as a safe and effective treatment option are significantly driving the market for this product type. Furthermore, ongoing clinical trials and research are exploring the role of VNS in treating other conditions, such as cluster headaches and anxiety disorders, which may contribute to market growth. As healthcare providers seek innovative approaches to treat hard-to-manage conditions, the demand for VNS devices is expected to rise.

Gastric Electrical Stimulators :

Gastric electrical stimulators (GES) are emerging as a valuable therapeutic option for patients suffering from gastroparesis, a condition characterized by delayed gastric emptying. GES devices work by sending electrical pulses to the stomach muscles, promoting gastric motility and alleviating symptoms. With the increasing prevalence of diabetes, which is a major contributor to gastroparesis, the demand for gastric electrical stimulators is likely to increase. Moreover, the growing recognition of GES as a minimally invasive treatment alternative is encouraging more healthcare providers to consider these devices for their patients. As further research validates the effectiveness of GES in improving gastrointestinal function, the market for this product type is poised for significant growth.

By Application

Chronic Pain Management :

Chronic pain management is one of the largest application segments within the implantable neurostimulators market. With a significant percentage of the population suffering from chronic pain conditions such as arthritis, fibromyalgia, and neuropathy, the demand for effective management solutions is on the rise. Implantable devices, particularly spinal cord stimulators, are increasingly being utilized to provide relief for patients who have not responded well to traditional pain management therapies. The growing acceptance of neurostimulation techniques among healthcare professionals is further driving the expansion of this application segment. As treatment options continue to evolve and clinical evidence supporting the efficacy of neurostimulation accumulates, the chronic pain management segment is expected to maintain robust growth in the coming years.

Parkinson’s Disease :

The application of implantable neurostimulators for Parkinson's Disease is gaining prominence, primarily due to the increasing prevalence of this neurological disorder. Deep brain stimulation (DBS) devices are widely utilized to alleviate the motor symptoms associated with Parkinson's, providing significant improvements in patient quality of life. The growing aging population and rising awareness of the therapeutic benefits of DBS are contributing factors to the expansion of this segment. Furthermore, ongoing advancements in DBS technology, including improved electrode designs and targeting techniques, are enhancing treatment efficacy. As more patients seek innovative therapies to manage Parkinson's Disease, this application segment is likely to experience substantial growth.

Urinary Incontinence :

Urinary incontinence is another key application area for implantable neurostimulators, specifically sacral nerve stimulators (SNS). The increasing prevalence of urinary incontinence, particularly among elderly populations, is driving the demand for effective treatment options. SNS devices have been shown to improve bladder control and overall quality of life for patients suffering from incontinence. The growing acceptance of SNS as a minimally invasive treatment is encouraging more healthcare providers to recommend these devices to their patients. Additionally, the rising awareness of women's health issues is contributing to the expansion of this application segment, as more women seek solutions for urinary incontinence. As the market continues to evolve, the application for urinary incontinence is expected to see significant growth.

Epilepsy :

Epilepsy is a prevalent neurological disorder that presents significant challenges for patients and healthcare providers. The use of vagus nerve stimulators (VNS) for treating epilepsy is becoming increasingly recognized as an effective alternative for patients who do not respond well to conventional antiepileptic drugs. The growing incidence of epilepsy worldwide and the demand for innovative therapeutic options are key drivers behind the expansion of this application segment. Additionally, ongoing research into the role of VNS in managing other neurological conditions may further bolster market growth. As healthcare systems continue to prioritize patient-centered care, the application of implantable neurostimulators for epilepsy is likely to see an upward trajectory in the upcoming years.

Gastroparesis :

Gastroparesis, a condition characterized by delayed gastric emptying, is gaining attention as a significant application for gastric electrical stimulators (GES). The rising prevalence of diabetes, which is a leading cause of gastroparesis, is driving the demand for innovative treatment solutions in this area. GES devices provide therapeutic benefits by enhancing gastric motility and improving patient outcomes. Increased awareness of the condition and its treatment options among patients and healthcare providers is contributing to the growth of this application segment. As more clinical studies validate the efficacy of GES in managing gastroparesis, the market is expected to expand, providing new opportunities for innovation and development.

By Distribution Channel

Hospitals :

Hospitals are among the primary distribution channels for implantable neurostimulators, serving as the main site for surgical procedures and patient care. Due to their advanced medical facilities and specialized healthcare teams, hospitals play a crucial role in the implantation and management of neurostimulation devices. The increasing prevalence of chronic pain and neurological disorders is driving higher patient volumes in hospitals, thereby bolstering the demand for neurostimulators. Furthermore, the adoption of advanced surgical techniques and protocols in hospitals enhances the effectiveness of these devices, promoting their utilization. As healthcare systems continue to evolve and prioritize complex medical care, hospitals are expected to remain a dominant distribution channel for neurostimulators.

Specialty Clinics :

Specialty clinics are emerging as a significant distribution channel for implantable neurostimulators, particularly for patients seeking targeted treatment options. These clinics often focus on specific conditions, including pain management and neurology, providing specialized services that cater to patients' unique needs. The increasing preference for outpatient procedures and minimally invasive therapies is driving the growth of specialty clinics as a distribution channel. Moreover, the high level of expertise and personalized care offered by these clinics encourages patients to seek treatment in these settings. As the demand for specialized care continues to rise, specialty clinics are likely to play an increasingly important role in the distribution of implantable neurostimulators.

Ambulatory Surgical Centers :

Ambulatory surgical centers (ASCs) are gaining traction as an essential distribution channel for implantable neurostimulators, particularly due to the increasing trend of outpatient procedures. ASCs offer a more cost-effective and efficient alternative to traditional hospitals, attracting a growing number of patients seeking surgical interventions for chronic pain and neurological disorders. The popularity of ASCs is further fueled by advancements in surgical techniques and anesthetic practices that allow for quicker recovery times. As patients become more aware of the benefits of outpatient care, ASCs are likely to continue their expansion as a preferred distribution channel for neurostimulators, ultimately contributing to market growth.

Online Sales :

The rise of e-commerce has opened new avenues for the distribution of implantable neurostimulators, with online sales becoming a notable channel in the market. Although direct-to-consumer sales of medical devices remain limited, online platforms are increasingly used for patient education and facilitating connections between healthcare providers and patients. Moreover, the growing trend of telemedicine and remote consultations is contributing to the rising acceptance of online sales channels. As patients continue to seek information and resources online, the availability of educational materials and support regarding neurostimulators through digital channels is likely to enhance market growth. As telehealth solutions evolve and integrate with traditional medical practices, online sales channels are expected to gain traction in the implantable neurostimulators market.

By Technology

Rechargeable :

Rechargeable implantable neurostimulators are becoming increasingly popular in the market due to their enhanced longevity and patient convenience. These devices allow patients to recharge their neurostimulation implants, reducing the frequency of battery replacement surgeries compared to non-rechargeable devices. The rising demand for long-lasting, efficient solutions for chronic pain and neurological disorders is driving the adoption of rechargeable neurostimulators. Moreover, advancements in battery technology are leading to longer-lasting devices, which, in turn, enhances patient satisfaction and encourages adherence to treatment protocols. As technological innovations continue to improve the efficiency and functionality of rechargeable neurostimulators, this segment is expected to witness significant growth.

Non-Rechargeable :

Non-rechargeable implantable neurostimulators have traditionally been a staple in neurostimulation therapies, providing reliable solutions for chronic pain management and neurological disorders. These devices are often favored for their simplicity and low-maintenance design, as they do not require regular recharging or battery replacements. The established presence of non-rechargeable neurostimulators in the market has built trust among healthcare providers and patients alike. However, the growing demand for more advanced solutions and the push for innovative technologies are driving a gradual shift towards rechargeable devices. Despite this trend, non-rechargeable devices are expected to maintain a significant share of the market as they continue to be utilized for specific applications and patient preferences.

By Region

The North America region is expected to dominate the implantable neurostimulators market, driven by the presence of advanced healthcare infrastructure, high healthcare expenditure, and a rising prevalence of neurological disorders. The United States, in particular, contributes a significant share to the North American market due to its robust healthcare system and technological advancements in medical devices. The market in this region is projected to grow at a CAGR of 11.5% over the forecast period, driven by increasing adoption of neurostimulators for chronic pain management and neurological disorders. Additionally, the favorable reimbursement policies and growing awareness regarding neurostimulation therapies are further propelling market growth in North America.

In Europe, the implantable neurostimulators market is also witnessing substantial growth, primarily driven by the increasing prevalence of chronic pain and neurological disorders among the aging population. The region is characterized by a growing focus on patient-centered care and advancements in medical technology, which are contributing to the acceptance of neurostimulation therapies. Furthermore, the presence of established healthcare systems and increasing investments in healthcare infrastructure are promoting market expansion. As the market continues to evolve, the European region is expected to maintain a significant share in the global implantable neurostimulators market, with particular growth observed in countries such as Germany, France, and the United Kingdom.

Opportunities

The implantable neurostimulators market is poised to benefit from various opportunities arising from technological advancements and increasing clinical applications. Innovations in device design, such as the development of wireless neurostimulators and improved programming capabilities, are enhancing patient experiences and treatment outcomes. Additionally, ongoing research into the efficacy of neurostimulation therapies for new applications, such as mental health disorders and neurorehabilitation, presents significant opportunities for market expansion. As healthcare providers continue to prioritize personalized treatment solutions, the demand for innovative neurostimulation devices is expected to increase. Furthermore, the growing trend of outpatient procedures and minimally invasive surgeries is likely to boost the adoption of neurostimulators, creating a favorable environment for market growth.

Another significant opportunity lies in the increasing awareness and acceptance of neurostimulation therapies within the healthcare community and among patients. As more healthcare providers recognize the benefits of implantable neurostimulators for chronic pain and neurological disorders, the adoption of these therapies is expected to rise. Additionally, the emphasis on patient education and support is crucial in promoting the utilization of neurostimulation devices. The commitment of healthcare systems to improve patient outcomes and reduce healthcare costs further amplifies the potential for growth in the implantable neurostimulators market. As the market evolves, identifying and leveraging these opportunities will be essential for stakeholders aiming to capitalize on the increasing demand for neurostimulation therapies.

Threats

Despite the promising growth prospects in the implantable neurostimulators market, several threats could impede progress. One of the primary challenges is the potential for device complications and adverse events associated with neurostimulation therapies. Patients may experience side effects or complications related to the surgical implantation process, device malfunction, or inappropriate device settings. Such risks can lead to negative patient experiences, reduced adherence to treatment, and, ultimately, lower market acceptance. Additionally, the stringent regulatory requirements for medical devices may pose challenges for manufacturers aiming to enter the market. Ensuring compliance with these regulations while maintaining product efficacy and safety may create barriers to entry and hinder the development of innovative solutions.

Another potential restraining factor is the high cost associated with implantable neurostimulators and their surgical procedures. The significant financial burden may limit patient access to these therapies, particularly in emerging markets with less robust healthcare systems. Moreover, the availability of alternative treatment options, such as pharmacological therapies and other non-invasive procedures, could lead to a preference for these alternatives over neurostimulation. The competitive landscape of the implantable neurostimulators market also presents challenges, with numerous established players vying for market share. As the market continues to evolve, these threats must be addressed to ensure sustained growth and success in the implantable neurostimulators market.

Competitor Outlook

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Stryker Corporation
• NeuroPace, Inc.
• Neuropace, Inc.
• Zynex, Inc.
• Stimwave Technologies, Inc.
• Elekta AB
• Nuvectra Corporation
• Hollywog LLC
• Inspire Medical Systems, Inc.
• Axonics Modulation Technologies, Inc.
• Saluda Medical Pty Limited
• Cleveland Medical Devices, Inc.

The competitive landscape of the implantable neurostimulators market is characterized by the presence of several established players and emerging companies striving to gain market share. With technological advancements driving innovation, companies are focusing on developing cutting-edge neurostimulators to address various neurological and chronic pain conditions. Collaboration and partnerships among industry players are also common, aimed at leveraging combined expertise for product development and market expansion. Furthermore, the competitive environment is influenced by ongoing clinical trials and research efforts that seek to validate the effectiveness of neurostimulation therapies, thereby enhancing market credibility and acceptance.

Medtronic plc is one of the leading players in the implantable neurostimulators market, known for its extensive portfolio of neurostimulation devices and commitment to innovation. The company has invested significantly in research and development to enhance the efficacy and functionality of its products. For instance, Medtronic’s implantable spinal cord stimulator systems are widely recognized for their advanced programming capabilities that allow for personalized pain management solutions. Boston Scientific Corporation is another major competitor, focusing on developing a wide range of neurostimulation technologies aimed at managing chronic pain and neurological disorders. The company has also made strategic acquisitions to expand its product offerings and enhance its competitive position in the market.

Abbott Laboratories is renowned for its innovative neurostimulation solutions, particularly in the fields of pain management and movement disorders. The company has successfully introduced multiple neurostimulator systems that cater to diverse patient needs, ensuring comprehensive treatment options. Additionally, Abbott's commitment to advancing neurostimulation technology is evident in its continuous investment in R&D and clinical trials. Stryker Corporation is also a significant player in the implantable neurostimulators sector, actively engaging in the innovation of spinal cord stimulators and other neurostimulation devices that address chronic pain and enhance quality of life for patients. As the market continues to evolve, these major companies, along with emerging players, are expected to contribute to the overall growth and development of the implantable neurostimulators market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Elekta AB
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Zynex, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Hollywog LLC
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Medtronic plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 NeuroPace, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Neuropace, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Stryker Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Nuvectra Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Saluda Medical Pty Limited
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Stimwave Technologies, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boston Scientific Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Inspire Medical Systems, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Cleveland Medical Devices, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Axonics Modulation Technologies, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Implantable Neurostimulators Market, By Technology
    • 6.1.1 Rechargeable
    • 6.1.2 Non-Rechargeable
  • 6.2 Implantable Neurostimulators Market, By Application
    • 6.2.1 Chronic Pain Management
    • 6.2.2 Parkinson’s Disease
    • 6.2.3 Urinary Incontinence
    • 6.2.4 Epilepsy
    • 6.2.5 Gastroparesis
  • 6.3 Implantable Neurostimulators Market, By Product Type
    • 6.3.1 Spinal Cord Stimulators
    • 6.3.2 Deep Brain Stimulators
    • 6.3.3 Sacral Nerve Stimulators
    • 6.3.4 Vagus Nerve Stimulators
    • 6.3.5 Gastric Electrical Stimulators
  • 6.4 Implantable Neurostimulators Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Implantable Neurostimulators Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Implantable Neurostimulators market is categorized based on

By Product Type

• Spinal Cord Stimulators
• Deep Brain Stimulators
• Sacral Nerve Stimulators
• Vagus Nerve Stimulators
• Gastric Electrical Stimulators

By Application

• Chronic Pain Management
• Parkinson’s Disease
• Urinary Incontinence
• Epilepsy
• Gastroparesis

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Online Sales

By Technology

• Rechargeable
• Non-Rechargeable

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Stryker Corporation
• NeuroPace, Inc.
• Neuropace, Inc.
• Zynex, Inc.
• Stimwave Technologies, Inc.
• Elekta AB
• Nuvectra Corporation
• Hollywog LLC
• Inspire Medical Systems, Inc.
• Axonics Modulation Technologies, Inc.
• Saluda Medical Pty Limited
• Cleveland Medical Devices, Inc.